GlassScriptPhysician profile
Michael A Novak
NPI 1902805872
$13,815.01
in general payments reported to CMS, 2019-2025
60 companies · $2,220 in 2025
The $2,220 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,409 · 2020: $1,429 · 2021: $2,063 · 2022: $2,327 · 2023: $2,112 · 2024: $2,254 · 2025: $2,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,586.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,588.03 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,117.44 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lilly USA, LLC | $635.27 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Amgen INC. | $613.76 | 2019-2024 | Aimovig |
| Allergan, INC. | $600.38 | 2019-2022 | |
| Ucb, INC. | $589.72 | 2019-2025 | Fintepla, Briviact, Rystiggo |
| Pfizer INC. | $558.90 | 2019-2025 | |
| Lundbeck LLC | $502.24 | 2020-2025 | Vyepti, Rexulti |
| Biogen, INC. | $473.34 | 2019-2025 | Vumerity, Tysabri |
| Neurocrine Biosciences, INC. | $367.72 | 2022-2025 | Ingrezza, Ongentys |
| Eisai INC. | $292.68 | 2023-2025 | |
| Avanir Pharmaceuticals, INC. | $287.33 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $280.03 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $252.01 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $231.39 | 2022 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Novak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.